These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

287 related articles for article (PubMed ID: 29581791)

  • 21. Uncommon mutation types of epidermal growth factor receptor and response to EGFR tyrosine kinase inhibitors in Chinese non-small cell lung cancer patients.
    Chen K; Yu X; Wang H; Huang Z; Xu Y; Gong L; Fan Y
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1179-1187. PubMed ID: 29063948
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association Between EGFR T790M Status and Progression Patterns During Initial EGFR-TKI Treatment in Patients Harboring EGFR Mutation.
    Oya Y; Yoshida T; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Hida T; Yatabe Y
    Clin Lung Cancer; 2017 Nov; 18(6):698-705.e2. PubMed ID: 28596108
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
    Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
    Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Re-biopsy by endobronchial ultrasound procedures for mutation analysis of non-small cell lung cancer after EGFR tyrosine kinase inhibitor treatment.
    Izumo T; Matsumoto Y; Chavez C; Tsuchida T
    BMC Pulm Med; 2016 Jul; 16(1):106. PubMed ID: 27457475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Predictors of Acquired
    Chai CS; Liam CK; Poh ME; Ong DB; Pang YK; Cheah PL; Ho GF; Alip A
    Cancer Manag Res; 2020; 12():5439-5450. PubMed ID: 32753961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EGFR tyrosine kinase inhibitor (TKI) in patients with advanced non-small cell lung cancer (NSCLC) harboring uncommon EGFR mutations: A real-world study in China.
    Xu J; Jin B; Chu T; Dong X; Yang H; Zhang Y; Wu D; Lou Y; Zhang X; Wang H; Han B
    Lung Cancer; 2016 Jun; 96():87-92. PubMed ID: 27133756
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan.
    Seto T; Nogami N; Yamamoto N; Atagi S; Tashiro N; Yoshimura Y; Yabuki Y; Saka H
    Oncol Ther; 2018 Dec; 6(2):203-215. PubMed ID: 32700028
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World T790M Mutation Frequency and Impact of Rebiopsy in Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.
    Pereira I; Gaspar C; Pina M; Azevedo I; Rodrigues A
    Cureus; 2020 Dec; 12(12):e12128. PubMed ID: 33489541
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EGFR-TKI rechallenge with bevacizumab in EGFR-mutant non-small cell lung cancer.
    Otsuka K; Hata A; Takeshita J; Okuda C; Kaji R; Masago K; Fujita S; Katakami N
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):835-41. PubMed ID: 26349474
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small cell lung cancer transformation and the T790M mutation: A case report of two acquired mechanisms of TKI resistance detected in a tumor rebiopsy and plasma sample of EGFR-mutant lung adenocarcinoma.
    Alì G; Bruno R; Giordano M; Prediletto I; Marconi L; Zupo S; Fedeli F; Ribechini A; Chella A; Fontanini G
    Oncol Lett; 2016 Nov; 12(5):4009-4012. PubMed ID: 27895763
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective Validation of Rapid Plasma Genotyping for the Detection of EGFR and KRAS Mutations in Advanced Lung Cancer.
    Sacher AG; Paweletz C; Dahlberg SE; Alden RS; O'Connell A; Feeney N; Mach SL; Jänne PA; Oxnard GR
    JAMA Oncol; 2016 Aug; 2(8):1014-22. PubMed ID: 27055085
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of epidermal growth factor receptor mutation by endobronchial ultrasound-guided transbronchial needle aspiration.
    Nakajima T; Yasufuku K; Suzuki M; Hiroshima K; Kubo R; Mohammed S; Miyagi Y; Matsukuma S; Sekine Y; Fujisawa T
    Chest; 2007 Aug; 132(2):597-602. PubMed ID: 17573511
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Gao W; He J; Jin SD; Xu J; Yu TF; Wang W; Zhu Q; Dai H; Wu H; Liu YQ; Shu YQ; Guo RH
    Onco Targets Ther; 2019; 12():9495-9504. PubMed ID: 31819477
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical utility of repeated rebiopsy for EGFR T790M mutation detection in non-small cell lung cancer.
    Lee EH; Kwak SH; Kim KY; Kim CY; Lee SH; Heo SJ; Chang YS; Kim EY
    Front Oncol; 2024; 14():1452947. PubMed ID: 39252953
    [TBL] [Abstract][Full Text] [Related]  

  • 35. T790M Correlates with Longer Progression-free Survival in Non-small Cell Lung Carcinomas Harboring
    Kogure Y; Shigematsu F; Oki M; Saka H
    In Vivo; 2018; 32(5):1199-1204. PubMed ID: 30150444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment and Outcomes of Metastatic Non-Small-Cell Lung Cancer Harboring Uncommon
    Jung HA; Park S; Sun JM; Lee SH; Ahn JS; Ahn MJ; Park K
    Biology (Basel); 2020 Oct; 9(10):. PubMed ID: 33036377
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The role of T790M mutation in EGFR-TKI re-challenge for patients with EGFR-mutant advanced lung adenocarcinoma.
    Zhang Q; Ke E; Niu F; Deng W; Chen Z; Xu C; Zhang X; Zhao N; Su J; Yang J; Yan H; Wu Y; Zhou Q
    Oncotarget; 2017 Jan; 8(3):4994-5002. PubMed ID: 27999211
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Meta-analysis of the impact of de novo and acquired
    Liu Y; Sun L; Xiong ZC; Sun X; Zhang SL; Ma JT; Han CB
    Onco Targets Ther; 2017; 10():2267-2279. PubMed ID: 28479857
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatiotemporal T790M Heterogeneity in Individual Patients with EGFR-Mutant Non-Small-Cell Lung Cancer after Acquired Resistance to EGFR-TKI.
    Hata A; Katakami N; Yoshioka H; Kaji R; Masago K; Fujita S; Imai Y; Nishiyama A; Ishida T; Nishimura Y; Yatabe Y
    J Thorac Oncol; 2015 Nov; 10(11):1553-9. PubMed ID: 26309190
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequency of T790M mutations after progression on epidermal growth factor receptor tyrosine kinase inhibitor in metastatic non-small cell lung cancer in Indian patients: real-time data from tertiary cancer hospital.
    Babu Koyyala VP; Batra U; Jain P; Sharma M; Goyal P; Medisetty P; Jajodia A; Maheshwari UD
    Lung India; 2018; 35(5):390-394. PubMed ID: 30168457
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.